Human medicines European public assessment report (EPAR): Dazublys, trastuzumab, Status: Opinion
On 25 April 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Dazublys, intended for the treatment of breast and gastric cancer. The …